BREAKING NEWS

Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia

22 November 2021

The European Commission granted marketing authorization for Brukinsa (zanubrutinib) for the treatment of  WM in adults who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy.

Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia

22 November 2021

The European Commission granted marketing authorization for Brukinsa (zanubrutinib) for the treatment of  WM in adults who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy.